Finchley Healthcare Ventures

Finchley Healthcare Ventures operates as a venture capital firm, strategically investing in nascent companies focused on developing novel therapies and allocating capital to specialized life sciences venture funds. The firm's approach emphasizes fostering innovation in new and transformative prescription medicines, actively seeking out breakthrough technologies and ideas that push the boundaries of medical research. While headquartered in North America, they maintain a global investment perspective.

The firm was founded in 2022 by David Goodman, who serves as its President, alongside Pierre Beauparlant, the Executive Managing Director. Goodman’s extensive career includes a significant tenure as a long-standing executive and former Chief Executive Officer of Pharmascience Inc., a prominent Canadian pharmaceutical company. This deep industry pedigree underscores the firm’s founding insight into leveraging strategic capital and expertise to nurture critical healthcare innovations.

Finchley Healthcare Ventures primarily partners with companies advancing innovative drug therapies, from those initiating their first clinical trials to those further along in development. The firm’s overarching mission is to back ventures that address significant unmet medical needs, ultimately striving to revolutionize patient care. They provide not only capital but also strategic guidance and industry connections, acting as a catalyst for their portfolio companies' success.